Aurora Cannabis stock analysis
Aurora Cannabis (21P) Stock Price & Analysis
21P Stock Chart & Stats
- Day’s Range
- EUR 4.56 - EUR 4.56
- 52-Week Range
- EUR 2.22 - EUR 5.39
- Previous Close
- EUR 4.58
- Volume
- N/A
- Average Volume (3M)
- 4,158
- Market Cap
- EUR 300.36M
- Enterprise Value
- EUR 250.46M
- Total Cash (Recent Filing)
- EUR 83.62M
- Total Debt (Recent Filing)
- EUR 21.43M
- Price to Earnings (P/E)
- ―
- Beta
- 0.88
- Next Earnings
- Feb 10, 2027 (Est.)
- EPS Estimate
- -0.05
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
International Medical Growth
International medical growth and rising geographic diversification strengthen Aurora’s revenue base beyond Canada. Greater exposure to regulated overseas markets, particularly Germany, can support durable demand, reduce reliance on one market, and provide a platform for further expansion.
Margin And Production Advantages
A 58% adjusted gross margin, combined with genetics-driven yield improvements, indicates meaningful operating advantages in selected products and markets. If sustained, these efficiencies can protect profitability, improve cost competitiveness, and support stronger EBITDA as capacity expands.
Balance Sheet Strength
Nearly $150 million of liquidity and zero debt provide substantial financial flexibility relative to the company’s current cash needs. This balance-sheet strength lowers solvency pressure and gives Aurora capacity to fund regulated-market expansion, acquisitions, and operational investments.
Bears Say
Revenue Contraction And Losses
Sharp TTM revenue contraction alongside renewed net and operating losses signals that the business has not yet established dependable scale economics. Persistent weakness in demand or mix can dilute fixed-cost absorption, limit reinvestment, and delay a durable return to profitability.
Negative Cash Generation
Negative operating and free cash flow means Aurora is still consuming cash despite improvement from earlier periods. If this pattern persists, ongoing funding needs could reduce strategic flexibility and eventually place pressure on liquidity, even though reported leverage remains low.
Canadian Reimbursement Headwind
The approximately 30% Canadian medical reimbursement reduction is a structural pressure on revenue and adjusted gross profit rather than a temporary trading issue. Lower reimbursement can weaken economics in that market, constrain margins, and make international growth more important to offset the decline.
Aurora Cannabis News
21P FAQ
What was Aurora Cannabis’s price range in the past 12 months?
What is Aurora Cannabis’s market cap?
When is Aurora Cannabis’s upcoming earnings report date?
How were Aurora Cannabis’s earnings last quarter?
Is Aurora Cannabis overvalued?
Does Aurora Cannabis pay dividends?
What is Aurora Cannabis’s EPS estimate?
How many shares outstanding does Aurora Cannabis have?
What happened to Aurora Cannabis’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Aurora Cannabis?
What is the TipRanks Smart Score and how is it calculated?
Aurora Cannabis Stock Smart Score
Company Description
Aurora Cannabis
Aurora Cannabis Inc. is a Canada-based firm specializing in the cultivation, processing, and global distribution of cannabis and its various derivative products. The company's operations encompass a broad spectrum of the cannabis industry, from facility engineering and design to genetic research, production, and the development of new products, all supported by extensive wholesale and retail networks. For medical users, Aurora offers diverse strains of dried cannabis, oils, capsules, and topical kits. Additionally, it markets a range of accessories, including vaporizers, consumable parts, herb mills (specifically for CanniMed products), grinders, and lockable vaporizer containers. The company is committed to advancing medical cannabis, with ongoing development across oral, topical, edible, and inhalable product categories. Aurora also provides key services such as patient counseling, design and construction assistance, and comprehensive analytical product testing for cannabis, alongside operating CanvasRX, a network dedicated to cannabis counseling and outreach. Its expansive brand family includes Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and WMMC. The corporate headquarters are located in Edmonton, Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Miguel Martin
- Employees
- 1,028
- Website
- www.auroramj.com
- Address
- 90B Street SW, Edmonton, AB, T6X 1V8, CA
Aurora Cannabis (21P) Earnings & Revenues
21P Company Deck
21P Earnings Call
Earnings Call SentimentNeutral
The call presents a balanced picture: material short-term financial headwinds (notably a large year-over-year decline in adjusted EBITDA, lower adjusted net income, and negative free cash flow) driven largely by an external 30% reimbursement cut in Canadian medical. Offsetting these negatives are clear strategic strengths—17% international revenue growth to $43M, a 58% adjusted gross margin, strong cash position with no debt, an accretive EU GMP acquisition (Safari), genetics-driven production advantages (up to 40% yield improvement), and market leadership in several regulated international markets. Management frames FY2027 as a transitionary year with expected sequential improvement in Q2 and reiterated long-term targets (sustained double-digit growth and superior margins). Given the mix of significant near-term financial declines and pronounced strategic/operational positives, the overall tone is balanced.
View all DE:21P earnings summaries21P Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 1 | 7 |
| Technical Analysis | 3 | 1 | 6 |
| Moving Averages | 11 | 0 | 1 |
